Fisher & Paykel Healthcare Corporation Limited
ASX: FPH
Fisher & Paykel poised for a short-term correction.
(Source: TradingView) 3-Month Performance Profile of FPH compared to the ASX 200 (XJO).
Fisher & Paykel after experiencing a considerable financial decline over the past few years with its revenues declining only modestly from $1.79 billion in 2021 to $1.61 billion in 2024 while its
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
